Lipitor Articles

Review Of US Second Qtr & Implications For Euro Firms

20 August 1998

W-L's Lipitor "Will Be World Top-Seller In 2005"

3 August 1998

"Extraordinary"Viagra Sales Lift Pfizer Earnings

10 July 1998

USA's Most-Dispensed Rx Drugs In April 1998

20 May 1998

Viagra Phenomenon Set To Transform Pharma Industry

6 May 1998

Stock Commentary New York

30 April 1998

Warner-Lambert's Profits Soar 37% In 1st Qtr

30 April 1998

Pfizer's Viagra Already Has 95% Share Of ED Market

30 April 1998

W-L To Stay Independent As Product Line Improves

30 April 1998

W-L To Stay Independent As Product Line Improves

24 April 1998

W-L Estimates 1998 EPS Growth Over 35%

23 April 1998

Unprecedented Take-Off For Pfizer's Viagra

21 April 1998

New Trial To Assess Benefits Of Aggressive Statin Treatment

20 April 1998

Pfizer Posts Double-Digit Sales & Earnings Growth

15 April 1998

Analysts Forecast Bright Outlook For US Majors

8 April 1998

Rx Drug Sales In USA Grew 12.6% Last Year

6 April 1998

Baycol Launched In Third Major Market

19 February 1998

Strong Growth For US Drug Firms In 1997

28 January 1998

Analysts Assess Outlook For US Drug Majors

8 January 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

News In Brief

7 November 1997

Stock Commentary New York

7 November 1997

Liver Warning On Rezulin Label Sparks Share Fall

6 November 1997

US 3rd Qtr Corporate Results Round-Up

30 October 1997

Merck's Sales Up 19% Amid Fears For The Future

17 October 1997

Pfizer's Healthy Growth Lifted By Alliance Products

16 October 1997

1998 Earnings Estimate "Achievable" For W-L

18 September 1997

Warner-Lambert Receives Boost From Goedecke Results

16 September 1997

Was It Such A Good Idea To Jump Into Generics?

16 September 1997

New Studies At European Cardiology Meeting

15 September 1997

GW's Zantac Knocked Off Top US Rx Drug Spot

4 September 1997

Pfizer Enters New Product Cycle With Strong Potential

7 August 1997

Solid Growth For US Firms Despite Strong $

24 July 1997

New York Stock Comment

24 July 1997

Stock Comment New York

17 July 1997

Pfizer's Good Volume Growth Marred By Strong $

17 July 1997

Stock Commentary New York

3 July 1997

Lipobay Selected For Large UK Study In Diabetics

24 June 1997

Outlook Favorable For Global Health Care

23 June 1997

New York Stock Comment

9 June 1997

New York Stock Comment

30 May 1997

ASCOT Study Announced

30 May 1997

Noncompliance "Will Cost US Firms $25 Bill In 1997"

5 May 1997

Declines In 1st Qtr At Warner-Lambert

5 May 1997

Warner-Lambert Set On Mid-Teens EPS Growth

5 May 1997

Forex Impacts Sales At Pfizer, Merck And S-P

22 April 1997

New York Stock Comment

21 April 1997

NEW YORK STOCK COMMENT

10 April 1997

First Launch Of Bayer's Lipobay

9 April 1997

Stock Comment New York

20 March 1997

NEW YORK STOCK COMMENT

17 March 1997

Lipitor Launched In Its Fourth Market, Canada

17 March 1997

Bayer's Lipobay Cleared In The UK, Its First Market

17 March 1997

Lipitor To Drive Outperformance At W-L?

14 March 1997

NEW YORK STOCK COMMENT

10 March 1997

New York Stock Comment

3 March 1997

First Launch Of Parke-Davis' Lipitor

10 February 1997

Strong Earnings Continue At Major US Drug Firms

10 February 1997

Parke-Davis To Launch Lipitor In The UK, Its First Market

3 February 1997

US 4th Qtr/Year-End Results See Strong Growth

27 January 1997

Continued Approval Of Blockbuster Products In '97?

23 December 1996

Atorvastatin: 1st Approvals In UK And Germany

9 December 1996

Canadian patent reform could hit generics